Predicting Hypoxia Status Using a Combination of Contrast-enhanced Computed Tomography and [F]-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2017 Dec 24

PMID 29273260

Citations 28

Authors

Mireia Crispin-Ortuzar

Aditya Apte

Milan Grkovski

Jung Hun Oh

Nancy Y Lee

Heiko Schoder

John L Humm

Joseph O Deasy

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Hypoxia is a known prognostic factor in head and neck cancer. Hypoxia imaging PET radiotracers such as F-FMISO are promising but not widely available. The aim of this study was therefore to design a surrogate for F-FMISO TBR based on F-FDG PET and contrast-enhanced CT radiomics features, and to study its performance in the context of hypoxia-based patient stratification.

Methods: 121 lesions from 75 head and neck cancer patients were used in the analysis. Patients received pre-treatment F-FDG and F-FMISO PET/CT scans. 79 lesions were used to train a cross-validated LASSO regression model based on radiomics features, while the remaining 42 were held out as an internal test subset.

Results: In the training subset, the highest AUC (0.873±0.008) was obtained from a signature combining CT and F-FDG PET features. The best performance on the unseen test subset was also obtained from the combined signature, with an AUC of 0.833, while the model based on the 90th percentile of F-FDG uptake had a test AUC of 0.756.

Conclusion: A radiomics signature built from F-FDG PET and contrast-enhanced CT features correlates with F-FMISO TBR in head and neck cancer patients, providing significantly better performance with respect to models based on F-FDG PET only. Such a biomarker could potentially be useful to personalize head and neck cancer treatment at centers for which dedicated hypoxia imaging PET radiotracers are unavailable.

Citing Articles

Is there a role for [F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature.

Sambasivan K, Barrington S, Connor S, Witney T, Blower P, Urbano T Clin Transl Imaging. 2024; 12(2):137-155.

PMID: 39286295 PMC: 7616449. DOI: 10.1007/s40336-023-00607-y.

Performance of radiomics in the differential diagnosis of parotid tumors: a systematic review.

Rao Y, Ma Y, Wang J, Xiao W, Wu J, Shi L Front Oncol. 2024; 14:1383323.

PMID: 39119093 PMC: 11306159. DOI: 10.3389/fonc.2024.1383323.

Multi-modality imaging parameters that predict rapid tumor regression in head and neck radiotherapy.

Aliotta E, Paudyal R, Diplas B, Han J, Hu Y, Oh J Phys Imaging Radiat Oncol. 2024; 31:100603.

PMID: 39040433 PMC: 11261256. DOI: 10.1016/j.phro.2024.100603.

State of the art: radiomics and radiomics-related artificial intelligence on the road to clinical translation.

Majumder S, Katz S, Kontos D, Roshkovan L BJR Open. 2024; 6(1):tzad004.

PMID: 38352179 PMC: 10860524. DOI: 10.1093/bjro/tzad004.

The application of F-FDG PET/CT imaging for human hepatocellular carcinoma: a narrative review.

Yao Y, Civelek A, Li X Quant Imaging Med Surg. 2023; 13(9):6268-6279.

PMID: 37711813 PMC: 10498267. DOI: 10.21037/qims-22-1420.

References

Bartlett R, Beattie B, Naryanan M, Georgi J, Chen Q, Carlin S . Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med. 2012; 53(10):1608-15. PMC: 3784982. DOI: 10.2967/jnumed.112.103523. View

Grabenbauer G, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P . Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol. 1998; 47(2):175-83. DOI: 10.1016/s0167-8140(98)00016-4. View

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

Zschaeck S, Haase R, Abolmaali N, Perrin R, Stutzer K, Appold S . Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. Acta Oncol. 2015; 54(9):1355-63. DOI: 10.3109/0284186X.2015.1074720. View

Clavo B, Robaina F, Fiuza D, Ruiz A, LLoret M, Rey-Baltar D . Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification. Clin Transl Oncol. 2016; 19(4):419-424. DOI: 10.1007/s12094-016-1541-x. View

Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling C . Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(1):101-8. PMC: 2840255. DOI: 10.1016/j.ijrobp.2008.10.049. View

Thorwarth D, Eschmann S, Holzner F, Paulsen F, Alber M . Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006; 80(2):151-6. DOI: 10.1016/j.radonc.2006.07.033. View

Facciabene A, Peng X, Hagemann I, Balint K, Barchetti A, Wang L . Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011; 475(7355):226-30. DOI: 10.1038/nature10169. View

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

10.

Dachs G, Tozer G . Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000; 36(13 Spec No):1649-60. DOI: 10.1016/s0959-8049(00)00159-3. View

11.

Welz S, Monnich D, Pfannenberg C, Nikolaou K, Reimold M, Fougere C . Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. 2017; 124(3):526-532. DOI: 10.1016/j.radonc.2017.04.004. View

12.

Lartigau E, Le Ridant A, Lambin P, Weeger P, Martin L, Sigal R . Oxygenation of head and neck tumors. Cancer. 1993; 71(7):2319-25. DOI: 10.1002/1097-0142(19930401)71:7<2319::aid-cncr2820710724>3.0.co;2-c. View

13.

Vordermark D, Horsman M . Hypoxia as a Biomarker and for Personalized Radiation Oncology. Recent Results Cancer Res. 2016; 198:123-42. DOI: 10.1007/978-3-662-49651-0_6. View

14.

Grkovski M, Schoder H, Lee N, Carlin S, Beattie B, Riaz N . Multiparametric Imaging of Tumor Hypoxia and Perfusion with F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. J Nucl Med. 2017; 58(7):1072-1080. PMC: 5493008. DOI: 10.2967/jnumed.116.188649. View

15.

Isa A, Ward T, West C, Slevin N, Homer J . Hypoxia in head and neck cancer. Br J Radiol. 2006; 79(946):791-8. DOI: 10.1259/bjr/17904358. View

16.

Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden S, Zelefsky M . Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2010; 82(1):291-8. DOI: 10.1016/j.ijrobp.2010.10.041. View

17.

Nordsmark M, Bentzen S, Rudat V, Brizel D, Lartigau E, Stadler P . Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005; 77(1):18-24. DOI: 10.1016/j.radonc.2005.06.038. View

18.

Thorwarth D, Eschmann S, Scheiderbauer J, Paulsen F, Alber M . Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005; 5:152. PMC: 1325034. DOI: 10.1186/1471-2407-5-152. View

19.

Foster B, Bagci U, Mansoor A, Xu Z, Mollura D . A review on segmentation of positron emission tomography images. Comput Biol Med. 2014; 50:76-96. PMC: 4060809. DOI: 10.1016/j.compbiomed.2014.04.014. View

20.

Lim R, Eaton A, Lee N, Setton J, Ohri N, Rao S . 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012; 53(10):1506-13. DOI: 10.2967/jnumed.111.101402. View